\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ underwent\\ successful\\ resection\\.\ \(0\)\
\-\ axial\\ ct\\ with\\ contrast\\ reveals\\ a\\ spiculated\\ non\\-enhancing\\ nodular\\ lesion\\ within\\ the\\ right\\ lower\\ lobe\\ with\\ areas\\ of\\ internal\\ hypodensity\\.\ \(0\)\
\-\ pet\\ \\(not\\ included\\)\\ evaluation\\ revealed\\ significant\\ suv\\ within\\ the\\ lesion\\.\ \(0\)\
\-\ large\\ cell\\ carcinoma\ \(1\)\
\-\ carcinoma\ \(1182\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ noncalcified\\ granuloma\ \(0\)\
\-\ hamartoma\ \(55\)\
\-\ avm\ \(1\)\
\-\ 79\\ year\\ old\\ female\\ with\\ incidental\\ findings\\ of\\ a\\ right\\ lung\\ nodule\\ on\\ virtual\\ colonography\\.\ \(1\)\
\-\ this\\ is\\ an\\ uncomplicated\\ presentation\\ of\\ a\\ common\\ malignancy\\.\\ \\ undoubtedly\\,\\ the\\ patient\\'s\\ disease\\ would\\ have\\ progressed\\ significantly\\ had\\ she\\ not\\ sought\\ screening\\ ct\\ colonography\\.\\ \\ one\\ of\\ the\\ benefits\\ of\\ screening\\ ct\\ colonography\\ is\\ in\\ finding\\ extra\\-colonic\\ disease\\.\\ \\ clinically\\ significant\\ findings\\ depend\\ upon\\ the\\ screened\\ population\\ where\\ age\\ is\\ the\\ most\\ important\\ factor\\ determining\\ risk\\ for\\ extra\\-colonic\\ malignancy\\.\\ \\ it\\ is\\ generally\\ agreed\\ that\\ in\\ older\\ populations\\ \\(\\>70\\ y\\/o\\)\\,\\ the\\ ct\\ colonography\\ technique\\ has\\ benefit\\ in\\ findings\\ significant\\ extra\\-colonic\\ disease\\ whereas\\ virtual\\ colonography\\ and\\ the\\ potential\\ benefit\\ in\\ discovering\\ extra\\-colonic\\ findings\\ important\\ in\\ a\\ younger\\ screening\\ population\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ colonography\\:\\ 0\\.5200692837024867\ \(0\)\
\-\ virtual\\:\\ 0\\.18970518725608318\ \(0\)\
\-\ screening\\:\\ 0\\.18373683873554997\ \(0\)\
\-\ benefit\\:\\ 0\\.16004266939168732\ \(0\)\
\-\ findings\\:\\ 0\\.1488399651048287\ \(0\)\
\-\ population\\:\\ 0\\.14265872049733053\ \(0\)\
\-\ significant\\:\\ 0\\.1305926032128027\ \(0\)\
\-\ important\\:\\ 0\\.12772979863043757\ \(0\)\
\-\ disease\\:\\ 0\\.1265909871903854\ \(0\)\
\-\ the\\:\\ 0\\.12035077024339531\ \(0\)\
\-\ discovering\\:\\ 0\\.11521251533903244\ \(0\)\
\-\ ct\\:\\ 0\\.11481290167003771\ \(0\)\
\-\ malignancy\\:\\ 0\\.11288533786373744\ \(0\)\
\-\ undoubtedly\\:\\ 0\\.10846097962604853\ \(0\)\
\-\ agreed\\:\\ 0\\.10401385674049736\ \(0\)\
\-\ noncalcified\\:\\ 0\\.10069225684655006\ \(0\)\
\-\ screened\\:\\ 0\\.10069225684655006\ \(0\)\
\-\ populations\\:\\ 0\\.09583207194184262\ \(0\)\
\-\ in\\:\\ 0\\.0937779728594421\ \(0\)\
\-\ sought\\:\\ 0\\.09308772138169176\ \(0\)\
\-\ depend\\:\\ 0\\.09308772138169176\ \(0\)\
\-\ carcinoma\\:\\ 0\\.09019463455039896\ \(0\)\
\-\ suv\\:\\ 0\\.08949359824801499\ \(0\)\
\-\ benefits\\:\\ 0\\.08718918542058225\ \(0\)\
\-\ determining\\:\\ 0\\.08718918542058225\ \(0\)\
\-\ is\\:\\ 0\\.08258869911463065\ \(0\)\
\-\ hypodensity\\:\\ 0\\.08200760087691979\ \(0\)\
\-\ spiculated\\:\\ 0\\.08165512908576239\ \(0\)\
\-\ whereas\\:\\ 0\\.08002133469584366\ \(0\)\
\-\ 79\\:\\ 0\\.07971748432871828\ \(0\)\
\-\ younger\\:\\ 0\\.07884572387978245\ \(0\)\
\-\ progressed\\:\\ 0\\.07829493964947991\ \(0\)\
\-\ technique\\:\\ 0\\.07776619278795208\ \(0\)\
\-\ uncomplicated\\:\\ 0\\.07653006740313006\ \(0\)\
\-\ hamartoma\\:\\ 0\\.07415973469410737\ \(0\)\
\-\ of\\:\\ 0\\.07377141637271294\ \(0\)\
\-\ successful\\:\\ 0\\.07320846750918279\ \(0\)\
\-\ lesion\\:\\ 0\\.07229117637374076\ \(0\)\
\-\ significantly\\:\\ 0\\.0708600715833879\ \(0\)\
\-\ factor\\:\\ 0\\.07070727324735908\ \(0\)\
\-\ older\\:\\ 0\\.06996870632166995\ \(0\)\
\-\ within\\:\\ 0\\.0694483556814447\ \(0\)\
\-\ granuloma\\:\\ 0\\.06822180404254871\ \(0\)\
\-\ potential\\:\\ 0\\.06736880429067431\ \(0\)\
\-\ avm\\:\\ 0\\.06667906994719613\ \(0\)\
\-\ included\\:\\ 0\\.06519722583623591\ \(0\)\
\-\ generally\\:\\ 0\\.06386489931521878\ \(0\)\
\-\ clinically\\:\\ 0\\.06265466406376972\ \(0\)\
\-\ 70\\:\\ 0\\.06224795785568117\ \(0\)\
\-\ nodular\\:\\ 0\\.060040019243893974\ \(0\)\
\-\ not\\:\\ 0\\.05952756065362279\ \(0\)\
\-\ nodule\\:\\ 0\\.059508614648824\ \(0\)\
\-\ upon\\:\\ 0\\.05931472008795941\ \(0\)\
\-\ where\\:\\ 0\\.059250715561616735\ \(0\)\
\-\ reveals\\:\\ 0\\.057350854187134676\ \(0\)\
\-\ incidental\\:\\ 0\\.05588661753182339\ \(0\)\
\-\ risk\\:\\ 0\\.05387045403241544\ \(0\)\
\-\ would\\:\\ 0\\.05337006964713781\ \(0\)\
\-\ underwent\\:\\ 0\\.05193667330371652\ \(0\)\
\-\ presentation\\:\\ 0\\.051900010564921516\ \(0\)\
\-\ areas\\:\\ 0\\.05118733611352215\ \(0\)\
\-\ internal\\:\\ 0\\.05081115031211262\ \(0\)\
\-\ right\\:\\ 0\\.04999249887576592\ \(0\)\
\-\ finding\\:\\ 0\\.04955757606595048\ \(0\)\
\-\ revealed\\:\\ 0\\.049435479041892806\ \(0\)\
\-\ patient\\:\\ 0\\.049043803848046734\ \(0\)\
\-\ resection\\:\\ 0\\.04832857141795866\ \(0\)\
\-\ age\\:\\ 0\\.04733313547003005\ \(0\)\
\-\ evaluation\\:\\ 0\\.045979525677327465\ \(0\)\
\-\ lung\\:\\ 0\\.045863076387813756\ \(0\)\
\-\ she\\:\\ 0\\.044880285980558335\ \(0\)\
\-\ with\\:\\ 0\\.04428929686585012\ \(0\)\
\-\ lobe\\:\\ 0\\.04356979827785561\ \(0\)\
\-\ one\\:\\ 0\\.04316663690252549\ \(0\)\
\-\ cell\\:\\ 0\\.043128874280091996\ \(0\)\
\-\ common\\:\\ 0\\.04275706610939774\ \(0\)\
\-\ metastatic\\:\\ 0\\.04134986882028284\ \(0\)\
\-\ most\\:\\ 0\\.039237350381774894\ \(0\)\
\-\ it\\:\\ 0\\.03859316408363445\ \(0\)\
\-\ lower\\:\\ 0\\.038526445573151505\ \(0\)\
\-\ large\\:\\ 0\\.03777616518263841\ \(0\)\
\-\ have\\:\\ 0\\.03766346702966633\ \(0\)\
\-\ had\\:\\ 0\\.03756409130691187\ \(0\)\
\-\ contrast\\:\\ 0\\.03663243301703388\ \(0\)\
\-\ female\\:\\ 0\\.0363811099778515\ \(0\)\
\-\ has\\:\\ 0\\.03443780850817637\ \(0\)\
\-\ that\\:\\ 0\\.03271819340917404\ \(0\)\
\-\ an\\:\\ 0\\.02883043437698594\ \(0\)\
\-\ this\\:\\ 0\\.025906755772983504\ \(0\)\
\-\ year\\:\\ 0\\.02323496403189906\ \(0\)\
\-\ for\\:\\ 0\\.02285136009732434\ \(0\)\
\-\ on\\:\\ 0\\.022770299377973834\ \(0\)\
\-\ old\\:\\ 0\\.022313608453022018\ \(0\)\
\-\ and\\:\\ 0\\.01557925886427144\ \(0\)\
